A citation-based method for searching scientific literature

Massimo Martino, Annalisa Paviglianiti. Expert Opin Biol Ther 2021
Times Cited: 3







List of co-cited articles
54 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Nina Shah, Ajai Chari, Emma Scott, Khalid Mezzi, Saad Z Usmani. Leukemia 2020
139
100

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Yu-Tzu Tai, Patrick A Mayes, Chirag Acharya, Mike Y Zhong, Michele Cea, Antonia Cagnetta, Jenny Craigen, John Yates, Louise Gliddon, William Fieles,[...]. Blood 2014
284
100

The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Shih-Feng Cho, Liang Lin, Lijie Xing, Yuyin Li, Kenneth Wen, Tengteng Yu, Phillip A Hsieh, Nikhil Munshi, Joachim Wahl, Katja Matthes,[...]. Blood Adv 2020
26
100

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos,[...]. Lancet 2019
290
100

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov,[...]. Lancet Oncol 2020
325
100

Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma.
Johanna Atamaniuk, Andreas Gleiss, Edit Porpaczy, Birgit Kainz, Thomas W Grunt, Markus Raderer, Bernadette Hilgarth, Johannes Drach, Heinz Ludwig, Heinz Gisslinger,[...]. Eur J Clin Invest 2012
52
100

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen,[...]. N Engl J Med 2015
918
100

γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
Sarah A Laurent, Franziska S Hoffmann, Peer-Hendrik Kuhn, Qingyu Cheng, Yuanyuan Chu, Marc Schmidt-Supprian, Stefanie M Hauck, Elisabeth Schuh, Markus Krumbholz, Heike Rübsamen,[...]. Nat Commun 2015
188
100

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.
Max S Topp, Johannes Duell, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Krönke, Thierry Facon, Alexey V Salnikov, Robin Lesley,[...]. J Clin Oncol 2020
163
100

Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.
Eric Sanchez, Abigail Gillespie, George Tang, Morgan Ferros, Nika Manik Harutyunyan, Suzie Vardanyan, Jillian Gottlieb, Mingjie Li, Cathy S Wang, Haiming Chen,[...]. Clin Cancer Res 2016
61
100

Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.
Hans C Lee, Noopur S Raje, Ola Landgren, Vijay V Upreti, Jin Wang, Ariel A Avilion, Xuguang Hu, Erik Rasmussen, Gataree Ngarmchamnanrith, Hisaki Fujii,[...]. Leukemia 2021
30
100

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.
S Hipp, Y-T Tai, D Blanset, P Deegen, J Wahl, O Thomas, B Rattel, P J Adam, K C Anderson, M Friedrich. Leukemia 2017
136
66


Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
Noopur S Raje, Philippe Moreau, Evangelos Terpos, Lotfi Benboubker, Norbert Grząśko, Sarah A Holstein, Albert Oriol, Shang-Yi Huang, Meral Beksac, Kazimierz Kuliczkowski,[...]. Br J Haematol 2017
30
66

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Ariana Berenson, Tanya M Spektor, Claudia Andreu-Vieyra, Sophia Petraki, Eric Sanchez,[...]. Haematologica 2017
86
66

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
Chiara Caraccio, Sachi Krishna, Darci J Phillips, Christian M Schürch. Front Immunol 2020
54
66

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Yu-Tzu Tai, Myles Dillon, Weihua Song, Merav Leiba, Xian-Feng Li, Peter Burger, Alfred I Lee, Klaus Podar, Teru Hideshima, Audie G Rice,[...]. Blood 2008
360
66

Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates.
Hui Zhao, John Atkinson, Sara Gulesserian, Zhilan Zeng, Jenny Nater, Jimmy Ou, Peng Yang, Karen Morrison, Jeffrey Coleman, Faisal Malik,[...]. Cancer Res 2018
43
66

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Shauna M Collins, Courtney E Bakan, Gina D Swartzel, Craig C Hofmeister, Yvonne A Efebera, Hakju Kwon, Gary C Starling, David Ciarlariello, Shakthi Bhaskar, Edward L Briercheck,[...]. Cancer Immunol Immunother 2013
209
66

Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.
Ji Li, Nicola J Stagg, Jennifer Johnston, Michael J Harris, Sam A Menzies, Danielle DiCara, Vanessa Clark, Maria Hristopoulos, Ryan Cook, Dionysos Slaga,[...]. Cancer Cell 2017
149
66

BCMA is essential for the survival of long-lived bone marrow plasma cells.
Brian P O'Connor, Vanitha S Raman, Loren D Erickson, W James Cook, Lehn K Weaver, Cory Ahonen, Ling-Li Lin, George T Mantchev, Richard J Bram, Randolph J Noelle. J Exp Med 2004
713
66

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S Raab,[...]. N Engl J Med 2018
290
66

Antibody-Drug Conjugates: The Last Decade.
Nicolas Joubert, Alain Beck, Charles Dumontet, Caroline Denevault-Sabourin. Pharmaceuticals (Basel) 2020
110
66

Immunomodulatory effects of CD38-targeting antibodies.
Niels W C J van de Donk. Immunol Lett 2018
51
66

Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M Voorhees, Brandi Reeves, Edward N Libby, Paul G Richardson, Larry D Anderson, Heather J Sutherland, Kwee Yong,[...]. Lancet Oncol 2018
145
66

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
Eric Sanchez, Mingjie Li, Alex Kitto, Jennifer Li, Cathy S Wang, Dylan T Kirk, Ori Yellin, Cydney M Nichols, Marissa P Dreyer, Cameryn P Ahles,[...]. Br J Haematol 2012
156
66

AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.
Rebecca L Goldstein, Ana Goyos, Chi-Ming Li, Petra Deegen, Pamela Bogner, Alexander Sternjak, Oliver Thomas, Matthias Klinger, Joachim Wahl, Matthias Friedrich,[...]. Blood Adv 2020
21
66

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Anja Seckinger, Jose Antonio Delgado, Samuel Moser, Laura Moreno, Brigitte Neuber, Anna Grab, Susanne Lipp, Juana Merino, Felipe Prosper, Martina Emde,[...]. Cancer Cell 2017
186
66

Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Asim V Farooq, Simona Degli Esposti, Rakesh Popat, Praneetha Thulasi, Sagar Lonial, Ajay K Nooka, Andrzej Jakubowiak, Douglas Sborov, Brian E Zaugg, Ashraf Z Badros,[...]. Ophthalmol Ther 2020
51
66

CAR T and CAR NK cells in multiple myeloma: Expanding the targets.
Urvi A Shah, Sham Mailankody. Best Pract Res Clin Haematol 2020
30
66


Bispecifics, trispecifics, and other novel immune treatments in myeloma.
Guido Lancman, Joshua Richter, Ajai Chari. Hematology Am Soc Hematol Educ Program 2020
26
66

Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
Kodandaram Pillarisetti, Gordon Powers, Leopoldo Luistro, Alexander Babich, Eric Baldwin, Yingzhe Li, Xiaochun Zhang, Mark Mendonça, Nate Majewski, Rupesh Nanjunda,[...]. Blood Adv 2020
32
66

Amanitins and their development as a payload for antibody-drug conjugates.
Andreas Pahl, Christian Lutz, Torsten Hechler. Drug Discov Today Technol 2018
42
66

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma.
Sabrina Prommersberger, Michael Reiser, Julia Beckmann, Sophia Danhof, Maximilian Amberger, Patricia Quade-Lyssy, Hermann Einsele, Michael Hudecek, Halvard Bonig, Zoltán Ivics. Gene Ther 2021
35
66

The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed.
Y Laabi, M P Gras, J C Brouet, R Berger, C J Larsen, A Tsapis. Nucleic Acids Res 1994
161
66

Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Xiuli Wang, Miriam Walter, Ryan Urak, Lihong Weng, Christian Huynh, Laura Lim, ChingLam W Wong, Wen-Chung Chang, Sandra H Thomas, James F Sanchez,[...]. Clin Cancer Res 2018
97
66

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Jeffrey A Zonder, Ann F Mohrbacher, Seema Singhal, Frits van Rhee, William I Bensinger, Han Ding, John Fry, Daniel E H Afar, Anil K Singhal. Blood 2012
278
66

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.
Gang An, Chirag Acharya, Xiaoyan Feng, Kenneth Wen, Mike Zhong, Li Zhang, Nikhil C Munshi, Lugui Qiu, Yu-Tzu Tai, Kenneth C Anderson. Blood 2016
108
66

Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member.
S Deaglio, M Morra, R Mallone, C M Ausiello, E Prager, G Garbarino, U Dianzani, H Stockinger, F Malavasi. J Immunol 1998
305
66

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Eric D Hsi, Roxanne Steinle, Balaji Balasa, Susann Szmania, Aparna Draksharapu, Benny P Shum, Mahrukh Huseni, David Powers, Amulya Nanisetti, Yin Zhang,[...]. Clin Cancer Res 2008
395
66

Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Ivo Demel, Julio Rodriguez Bago, Roman Hajek, Tomas Jelinek. Br J Haematol 2021
13
66

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Laura Moreno, Cristina Perez, Aintzane Zabaleta, Irene Manrique, Diego Alignani, Daniel Ajona, Laura Blanco, Marta Lasa, Patricia Maiso, Idoia Rodriguez,[...]. Clin Cancer Res 2019
117
66

Anti-BCMA antibodies in the future management of multiple myeloma.
Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Meletios Athanasios Dimopoulos, Evangelos Terpos. Expert Rev Anticancer Ther 2019
15
66

ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP.
R Aarhus, R M Graeff, D M Dickey, T F Walseth, H C Lee. J Biol Chem 1995
339
66

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
Yu-Tzu Tai, Chirag Acharya, Gang An, Michele Moschetta, Mike Y Zhong, Xiaoyan Feng, Michele Cea, Antonia Cagnetta, Kenneth Wen, Hans van Eenennaam,[...]. Blood 2016
177
66

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Larysa Sanchez, Alexandra Dardac, Deepu Madduri, Shambavi Richard, Joshua Richter. Ther Adv Hematol 2021
15
66

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
Meletios A Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Katja Weisel, Jesus San-Miguel, Ofer Shpilberg, Sebastian Grosicki, Ivan Špička, Adam Walter-Croneck,[...]. Blood Cancer J 2020
44
66

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.
Eugenia Zah, Eunwoo Nam, Vinya Bhuvan, Uyen Tran, Brenda Y Ji, Stanley B Gosliner, Xiuli Wang, Christine E Brown, Yvonne Y Chen. Nat Commun 2020
76
66


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.